BIT Capital GmbH Purchases Shares of 31,614 uniQure N.V. $QURE

BIT Capital GmbH purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,614 shares of the biotechnology company’s stock, valued at approximately $757,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. CIBC Private Wealth Group LLC purchased a new stake in uniQure during the 3rd quarter worth $50,000. Torren Management LLC purchased a new stake in uniQure during the 4th quarter worth $28,000. FNY Investment Advisers LLC increased its stake in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the period. Finally, IFP Advisors Inc purchased a new stake in uniQure during the 4th quarter worth $48,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

NASDAQ:QURE opened at $26.45 on Friday. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $21.39 and a 200-day moving average of $21.86. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -7.60 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, Director Jack Kaye sold 2,645 shares of uniQure stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45. Following the sale, the director owned 20,439 shares in the company, valued at $613,374.39. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider owned 169,669 shares in the company, valued at $4,251,905.14. This represents a 20.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. HC Wainwright cut their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. The Goldman Sachs Group upped their price target on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Chardan Capital upped their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.